Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cataract (disease) in which the cause of the disease is a mutation in the CRYGD gene.
Features include: Developmental cataract.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Developmental cataract |
CRYGD encodes crystallin gamma D (174 aa). Crystallins are the dominant structural components of the vertebrate eye lens Highest expression in Ovary (8.4 TPM) and Brain Hypothalamus (2.9 TPM).
Cataract 4 multiple types is associated with mutations in the CRYGD gene on chromosome 2.
CRYGD is classified as a druggable target (Enzyme category) with score 26.1.
Genetic testing for CRYGD is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cataract 4 multiple types has been reported in the published literature.
No clinical trials have been registered for cataract 4 multiple types.
59 publications have been identified in PubMed for cataract 4 multiple types. Research spans Case Report / Case Series (29%), Clinical Trial Publication (20%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 29% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 3:15 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
12 |
20% |
Disease patterns and progression | 11 | 19% |
Research summaries | 9 | 15% |
Laboratory research | 4 | 7% |
New treatment approaches | 3 | 5% |
Other research | 2 | 3% |
Testing and diagnosis research | 1 | 2% |
Firn K (2026). [PMID: 40465813](https://pubmed.ncbi.nlm.nih.gov/40465813/). *Unknown Journal*. [Other]
Zhuang J (2026). [PMID: 42111499](https://pubmed.ncbi.nlm.nih.gov/42111499/). *Hum Mutat*. [Gene Therapy / Novel Therapeutics]
Uc-Santos E (2026). [PMID: 41825345](https://pubmed.ncbi.nlm.nih.gov/41825345/). *J Inorg Biochem*. [Basic Science / Preclinical]
Gorgi HA (2026). [PMID: 41885317](https://pubmed.ncbi.nlm.nih.gov/41885317/). *Eur J Ophthalmol*. [Basic Science / Preclinical]
Ing A (2026). [PMID: 42091610](https://pubmed.ncbi.nlm.nih.gov/42091610/). *Ophthalmic Genet*. [Gene Therapy / Novel Therapeutics]
Oshika T (2026). [PMID: 42091627](https://pubmed.ncbi.nlm.nih.gov/42091627/). *Sci Rep*. [Clinical Trial Publication]
Paredes-Hernández M (2026). [PMID: 41720340](https://pubmed.ncbi.nlm.nih.gov/41720340/). *Arch Soc Esp Oftalmol (Engl Ed)*. [Case Report / Case Series]
Kang S (2026). [PMID: 41236190](https://pubmed.ncbi.nlm.nih.gov/41236190/). *Ophthalmic Genet*. [Case Report / Case Series]
Maitra P (2026). [PMID: 40736062](https://pubmed.ncbi.nlm.nih.gov/40736062/). *J Pediatr Ophthalmol Strabismus*. [Epidemiology / Natural History]
Huang T (2026). [PMID: 41822754](https://pubmed.ncbi.nlm.nih.gov/41822754/). *Front Genet*. [Case Report / Case Series]